Drug Approval | August 23, 2024
Wanbury receives EIR from FDA for Patalganga facility
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
USFDA has determined that the inspection classification of this facility is "No Action Indicated" (NAI) with zero 483 observation
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The tele-icu services which had a soft launch four months ago have already provided valuable assistance to 250+ patients in some of the remotest villages in India
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
Sigachi's entry into the coatings market is strategically timed to capitalize on the industry's growth potential
AGEasy has made significant strides in addressing the pressing health concerns of seniors in India
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
Coveris’ security labels also work seamlessly with self-checkouts where around 80% of retail sales now typically occur
This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
Subscribe To Our Newsletter & Stay Updated
